Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 9 de 9
Filter
1.
Int J Environ Health Res ; 34(3): 1410-1420, 2024 Mar.
Article in English | MEDLINE | ID: mdl-37211801

ABSTRACT

To evaluate the association between ATP2B1 gene polymorphisms and skeletal fluorosis, a cross-sectional study was conducted. In China, 962 individuals were recruited, including 342 cases of skeletal fluorosis. Four TP2BA1 polymorphisms (rs2070759, rs12817819, rs17249754, and rs7136259) were analysed. The results suggested that rs17249754 and rs7136259 were associated with skeletal fluorosis. After controlling confounders, the protective effect of GG genotype in rs17249754 was apparent in individuals over 45 years old, female, with urine fluoride concentration below 1.6 mg/L, serum calcium above 2.25 mmol/L or serum phosphorus between 1.1 and 1.3. Heterozygote TC in rs7136259 increased the risk of skeletal fluorosis in subjects who are elderly, female, with urinary fluoride more than 1.6 mg/L, serum calcium more than 2.25 mmol/L and blood phosphorus between 1.1 and 1.3 mmol/L. Four loci were found to be tightly related by linkage disequilibrium analysis, and the frequency of distribution of haplotype GCGT was lower in the skeletal fluorosis group.


Subject(s)
Bone Diseases, Metabolic , Fluorosis, Dental , Humans , Female , Aged , Middle Aged , Fluorides , Haplotypes , Calcium , Polymorphism, Single Nucleotide , Cross-Sectional Studies , Bone Diseases, Metabolic/genetics , China/epidemiology , Phosphorus , Fluorosis, Dental/epidemiology , Fluorosis, Dental/genetics , Plasma Membrane Calcium-Transporting ATPases/genetics
2.
Food Chem ; 386: 132811, 2022 Aug 30.
Article in English | MEDLINE | ID: mdl-35366632

ABSTRACT

Soy protein papain hydrolysate (SPAH) and soy protein pepsin hydrolysate (SPEH) were used as protective agents for mulberry anthocyanin extracts (MAEs) to inhibit its color fading and enhance the anthocyanin stability at pH 6.3. Both SPAH and SPEH showed a significant protective effect on total anthocyanins in MAEs solutions. 1.0 mg/mL of SPEH presented the best protective effect on MAEs by increasing its half-life from 1.8 to 5.7 days. SPAH/SPEH-cyaniding-3-O-glucoside (C3G) interactions were investigated at pH 6.3 by fluorescence, Fourier-transform infrared spectroscopy (FT-IR), and Circular Dichroism (CD). Their association was mainly driven by hydrophobic interactions, and SPEH showed a higher binding affinity for C3G than SPAH, with a KA value of 2.62 × 105 M-1 at 300 K. The second structures of SPAH and SPEH were altered by C3G, with a decrease in the ß-sheets and an increase in the turns and random coils.


Subject(s)
Anthocyanins , Morus , Anthocyanins/chemistry , Food Handling , Morus/metabolism , Papain , Plant Extracts/chemistry , Protein Hydrolysates/chemistry , Soybean Proteins/chemistry , Glycine max/chemistry , Spectroscopy, Fourier Transform Infrared
3.
Med Oncol ; 38(8): 94, 2021 Jul 14.
Article in English | MEDLINE | ID: mdl-34259934

ABSTRACT

Ideal lead compounds and candidate drugs with inhibitory effect on BCL2 were screened from ZINC database, which laid a foundation for drug development and compound improvement of drug treatment for diffuse large B-cell lymphoma (DLCBL). Identification of potential BCL2 inhibitors by computer-aided virtual screening. Libdock was applied to 17,931 compounds and the top 20 were selected for further analysis. Selected compounds were performed absorption, distribution, metabolism, and excretion (ADME) and toxicity prediction. The binding affinity between the selected ligands and BCL2 was confirmed by Molecular docking. The new natural compounds, ZINC00000255131 and ZINC00013298233, were found to bind closely with BCL2. Furthermore, they all scored lower in ames-induced mutagenicity, rodent carcinogenicity, non-developmental toxicity potential, and cytochrome P4502D6 tolerance. Molecular dynamics simulation shows that the combinations of ZINC00000255131 and ZINC00013298233 with BCL2 in the natural environment are more stable. Two new compounds, ZINC00000255131 and ZINC00013298233, were found to be potential inhibitors of BCL2. These compounds have been proved to be safe, which is of great significance for the development and improvement of DLCBL drugs.


Subject(s)
Antineoplastic Agents/administration & dosage , Biological Products/administration & dosage , Computer Simulation , Drug Delivery Systems/methods , Lymphoma, Large B-Cell, Diffuse/drug therapy , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Biological Products/metabolism , Drug Evaluation, Preclinical/methods , Humans , Lymphoma, Large B-Cell, Diffuse/metabolism , Molecular Docking Simulation/methods , Molecular Dynamics Simulation , Protein Structure, Secondary , Protein Structure, Tertiary , Proto-Oncogene Proteins c-bcl-2/metabolism
4.
Aging (Albany NY) ; 13(2): 1898-1912, 2021 01 23.
Article in English | MEDLINE | ID: mdl-33486472

ABSTRACT

OBJECT: This study was designed to screen ideal lead compounds and drug candidates with an inhibitory effect on PARP from the drug library (ZINC database). RESULTS: Two effective natural compounds ZINC000003938684 and ZINC000014811844 were found to bind to PARP in the ZINC database, showing a higher binding affinity. Also, they were predicted to have lower rodent carcinogenicity, Ames mutagenicity, developmental toxicity potential, and high tolerance to cytochrome P4502D6. Molecular dynamics simulation showed that ZINC000003938684 and ZINC000014811844 had a more favorable potential energies with PARP, which could exist stably in natural circumstances. CONCLUSION: This study suggested that ZINC000003938684 and ZINC000014811844 were ideal potential inhibitors of PARP targeting. These compounds were safe drug candidates and had important implications for the design and improvement of CMET target drugs. METHODS: A battery of computer-aided virtual techniques were used to identify potential inhibitors of PARP. LibDock is used for structure-based screening followed by ADME (absorption distribution, metabolic excretion) and toxicity prediction. Molecular docking was performed to demonstrate the binding affinity mechanism between the ligand and PARP. Molecular dynamics simulations were used to evaluate the stability of ligand-receptor complexes.


Subject(s)
Drug Design , Drug Evaluation, Preclinical , Poly(ADP-ribose) Polymerase Inhibitors/pharmacology , Humans , Molecular Docking Simulation , Molecular Dynamics Simulation
5.
Medicine (Baltimore) ; 98(19): e15586, 2019 May.
Article in English | MEDLINE | ID: mdl-31083242

ABSTRACT

BACKGROUND: There are a number of complementary and alternative therapies for the primary dysmenorrhea (PD) and their efficacy has been assessed by several systematic reviews. But only pair-wised drugs have been evaluated in the traditional meta-analyses and conflicting interpretation of results also existed among different studies. Here, a protocol for a network meta-analysis will be presented aimed to compare the efficacy and safety of different complementary and alternative therapies for PD. METHODS: All randomized controlled trials of complementary and alternative therapies for the PD will be included. The primary outcomes of our interest are pain intensity and pain duration and the secondary outcomes are quality of life, clinical effective rate, and adverse events. We will search relevant database, the ongoing trial, previous relevant reviews and reference lists, and so on. The identification and selection of studies and data extraction will be conducted by two independent reviewers. We will perform a battery of pairwise meta-analyses and Bayesian network meta-analyses to assess the relative outcomes of different complementary and alternative therapies. We will use the surface under the cumulative ranking curve values and the mean ranks to get the treatment hierarchy, and then use the node-splitting method to evaluate consistency. The softwares WinBUGS 1.4.3 and STATA will be selected and the quality of the evidence will be evaluated using the Grading of Recommendations Assessment, Development and Evaluation instrument. ETHICS AND DISSEMINATION: This review does not require ethical approval. PROSPERO REGISTRATION NUMBER: PROSPERO CRD42018107763.


Subject(s)
Complementary Therapies/methods , Dysmenorrhea/therapy , Network Meta-Analysis , Female , Humans
6.
Medicine (Baltimore) ; 98(17): e15239, 2019 Apr.
Article in English | MEDLINE | ID: mdl-31027071

ABSTRACT

RATIONALE: Many studies have reported radical resection for liver metastasis and the primary tumor could represent an important prognostic factor in patients affected by colorectal liver metastases (CRLM). However, resection of huge liver metastases from colon cancer has been seldom reported. PATIENT CONCERNS: A 58-year-old man presented with huge liver metastases from colon cancer. Laboratory tests revealed elevated tumor markers and a wild-type mutation in the K-RAS gene. A computed tomography scan demonstrated unresectable liver masses with a 16.5-cm maximum diameter and intrahepatic duct dilatation due to compression by the liver metastases. DIAGNOSIS: The patient was diagnosed with stage IV descending colon carcinoma with multiple huge hepatic metastases. INTERVENTIONS: He was administered 3 treatment courses, including 9 cycles of combined chemotherapy with mFOLFOX6 plus cetuximab (mFOLFOX6 + Cet), and the liver masses reduced. After a preoperative assessment by a multidisciplinary team when the 9 cycles of systemic chemotherapy had been completed, the patient underwent hepatectomy, followed 4 months later by a laparoscopic colectomy. We used a reverse strategy (liver-first) for the patient. OUTCOMES: In this case, liver-first treatment (systemic chemotherapy of mFOLFOX6 + Cet) was an effective treatment for unresectable CRLM. No postoperative complications occurred. The patient continued to receive postoperative chemotherapy (mFOLFOX6 + Cet) at the latest follow-up. During the 17 months of follow-up, tumor recurrence was un-noted. LESSONS: Treating colorectal cancer patients with huge hepatic metastases is possible, and surgeons should consider various treatment options in the management of these patients.


Subject(s)
Colonic Neoplasms/pathology , Liver Neoplasms/secondary , Liver Neoplasms/surgery , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cetuximab/therapeutic use , Chemotherapy, Adjuvant , Fluorouracil/therapeutic use , Humans , Leucovorin/therapeutic use , Liver Neoplasms/drug therapy , Male , Middle Aged , Organoplatinum Compounds/therapeutic use
7.
Pak J Pharm Sci ; 30(4): 1357-1362, 2017 Jul.
Article in English | MEDLINE | ID: mdl-29039338

ABSTRACT

Phragmitesaustralis (P. australis), a worldwide distributed wetland grass, is traditionally used as food-making helper and spice in China. The pharmacological effect of this plant is poorly understood. Here, we demonstrated that lipopolysaccharide (LPS)-induced production of inflammatory mediators nitric oxide (NO) and reactive oxygen species (ROS), and the pro-inflammatory cytokines tumor necrosis factor-a (TNF-a) and interleukin-1ß (IL-1ß) in RAW264.7 macrophage were significantly inhibited by the crude extract. The inflammation pertinent signaling extra cellular signal-regulated kinase 1/2 (Erk1/2), P38MAPK, C-Jun and NF-kappaB (NF-κB) activated by LPS could be dramatically inhibited by this extract. It also remarkably inhibited bovine herpes virus type 1 (BoHV-1) replication in MDBK cells. Taken together, here, for the first time we provided P. australisa a novel natural herb as a potential candidate for the generation of antiviral and anti-inflammatory agent.


Subject(s)
Anti-Inflammatory Agents/pharmacology , Antiviral Agents/pharmacology , Plant Extracts/pharmacology , Poaceae/chemistry , Virus Replication/drug effects , Animals , Cells, Cultured , Herpesvirus 1, Bovine/drug effects , Inflammation/chemically induced , Inflammation/metabolism , Inflammation Mediators/metabolism , Lipopolysaccharides , Macrophages/metabolism , Mice , Plant Extracts/chemistry , Signal Transduction/drug effects
8.
Hum Vaccin Immunother ; 12(3): 829-36, 2016 03 03.
Article in English | MEDLINE | ID: mdl-26479036

ABSTRACT

The rapid occurrence of emerging infectious diseases demonstrates an urgent need for a new preclinical experimental model that reliably replicates human immune responses. Here, a new homozygous humanized human leukocyte antigen (HLA)-A11/DR1 transgenic mouse (HLA-A11(+/+)/DR01(+/+)/H-2-ß2m(-/-)/IAß(-/-)) was generated by crossing HLA-A11 transgenic (Tg) mice with HLA-A2(+/+)/DR01(+/+)/H-2-ß2m(-/-)/IAß(-/-) mice. The HLA-A11-restricted immune response of this mouse model was then examined. HLA-A11 Tg mice expressing a chimeric major histocompatibility complex (MHC) molecule comprising the α1, α2, and ß2m domains of human HLA-A11 and the α3 transmembrane and cytoplasmic domains of murine H-2D(b) were generated. The correct integration of HLA-A11 and HLA-DR1 into the genome of the HLA-A11/DR1 Tg mice (which lacked the expression of endogenous H-2-I/II molecules) was then confirmed. Immunizing mice with a recombinant HBV vaccine or a recombinant HIV-1 protein resulted in the generation of IFN-γ-producing cytotoxic T lymphocyte (CTL) and antigen-specific antibodies. The HLA-A11-restricted CTL response was directed at HLA immunodominant epitopes. These mice represent a versatile animal model for studying the immunogenicity of HLA CTL epitopes in the absence of a murine MHC response. The established animal model will also be useful for evaluating and optimizing T cell-based vaccines and for studying differences in antigen processing between mice and humans.


Subject(s)
AIDS Vaccines/immunology , Drug Evaluation, Preclinical/methods , HLA-A11 Antigen/genetics , HLA-DR1 Antigen/genetics , Hepatitis B Vaccines/immunology , Mice, Transgenic , AIDS Vaccines/administration & dosage , Animals , Crosses, Genetic , HIV Antibodies/blood , Hepatitis B Antibodies/blood , Hepatitis B Vaccines/administration & dosage , Homozygote , Humans , Interferon-gamma/metabolism , Models, Animal , T-Lymphocytes/immunology
9.
J Agric Food Chem ; 60(20): 5089-98, 2012 May 23.
Article in English | MEDLINE | ID: mdl-22551191

ABSTRACT

A multiresidue method for determining pesticides in rapeseed, rapeseed oil, and rapeseed meal by use of liquid chromatography-tandem mass spectrometry is developed. Samples were extracted with acetonitrile or acidified acetonitrile and cleaned up by a 12 h freezing step. The recovery data were obtained by spiking blank samples at three concentration levels. The recoveries of 27 selected pesticides in rapeseed, rapeseed oil, and rapeseed meal were in the range of 70-118%, at the concentration level of 10 µg kg(-1), with intraday and interday precisions of lower than 22 and 27%, respectively. Linearity was studied between 2 and 500 µg L(-1) with determination coefficients (R(2)) of higher than 0.98 for all compounds in the three matrices. The limits of quantitation (LOQs) of pesticides in rapeseed, rapeseed oil, and rapeseed meal ranged from 0.3 to 18 µg kg(-1). The n-octanol-water partition coefficient showed more influence than water solubility in extracting pesticides by acetonitrile from matrices of high fat content. This method was successfully applied for routine analysis in commercial products.


Subject(s)
Brassica rapa/chemistry , Chromatography, Liquid/methods , Pesticide Residues/analysis , Plant Oils/chemistry , Tandem Mass Spectrometry/methods , Acetonitriles , Fatty Acids, Monounsaturated , Rapeseed Oil , Reproducibility of Results , Temperature
SELECTION OF CITATIONS
SEARCH DETAIL